Common medicines and over the counter products can cause memory loss that can mimic Dementia Not all memory loss or confusion comes from Alzheimer’s or other true dementias . Sometimes, the medicines we take can cause very similar symptoms—like forgetfulness, slowed thinking, or trouble finding words. The good news is that these side effects often improve once the medicine is stopped or changed. Never stop a medication on your own—always talk with me first. 1. Anticholinergic Drugs These medicines block a brain chemical called acetylcholine, which is important for memory. They include: Older allergy medicines like diphenhydramine (Benadryl, many “PM” sleep aids). Bladder medicines like oxybutynin. Some older antidepressants and stomach medicines. Why it matters:  People who take these drugs for years have a higher chance of developing dementia. Even short-term, they can cause brain fog and confusion. 2. Anxiety and Sleep Pills This group includes benzodiazepines  (like lorazepam, alprazolam, diazepam) and “Z-drugs” (zolpidem/Ambien). Why it matters:  They can cause drowsiness, memory problems, and confusion, especially in older adults. Using them for a long time may raise dementia risk. 3. Antipsychotics Medicines used for severe mood or behavior problems (like risperidone, haloperidol, quetiapine). Why it matters:  They can increase confusion and even raise the risk of death in older adults with dementia. They should be used only when absolutely necessary. 4. Strong Pain Pills (Opioids) Examples: oxycodone, morphine, hydrocodone. Why it matters:  They can make thinking slow, cause confusion, and trigger delirium. This is more common at higher doses. 5. Seizure and Nerve Pain Medicines Topiramate is well known for causing word-finding problems and mental “slowness.” Gabapentin and pregabalin can also make people groggy or forgetful. 6. Steroids Prednisone and other “cortisone” medicines can affect mood and memory. Some people feel hyper and can’t sleep, while others may feel depressed or confused. 7. Other Medicines to Watch Certain stomach drugs  (like ranitidine and cimetidine) can sometimes cause confusion in older adults. Some antibiotics  (like ciprofloxacin and levofloxacin) have FDA warnings about confusion and memory changes. What You Can Do Bring all your medicines (including over-the-counter ones) to your doctor visits. Ask about your “anticholinergic burden.”  This is the total effect of all memory-blocking drugs you take. Never stop a drug suddenly without medical advice.  Some need to be tapered off slowly. Ask about safer options.  Many times, there are alternatives with fewer brain effects. Report new confusion or memory changes right away. Key Message Not all memory problems mean you have dementia. Sometimes the cause is the medicines themselves—and that means we can often fix it. By reviewing your medication list together, we can lower your risk, protect your brain, and help you feel clearer. Some medicines are better than others in preventing confusion, memory loss or dizziness: 1. Benedryl is a problem. Better to use Claritin, if you are over 60 years of age. 2. Prilosec is a problem. Better to use Famotidine. 3. Oxybutinin, Ditropan. Better to use myrbetriq. 4. Statins like atorvastatin and lovastatin. Better to use Rosuvastatin. References Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, Yu O, Crane PK, Larson EB. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med.  2015;175(3):401-407. doi:10.1001/jamainternmed.2014.7663. Link Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, Myint PK, Grossi CM, Mattishent K, Bennett K, Campbell N, Boustani M, Robinson L, Brayne C, Matthews FE, Savva GM. Anticholinergic drugs and risk of dementia: case-control study. BMJ.  2018;361:k1315. doi:10.1136/bmj.k1315. Link Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med.  2019;179(8):1084-1093. doi:10.1001/jamainternmed.2019.0677. Link Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, Gao S, Boustani M, Crane PK, Petersen RC, Jack CR Jr, Jagust WJ, Aisen PS, Weiner MW, Saykin AJ. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol.  2016;73(6):721-732. doi:10.1001/jamaneurol.2016.0580. Link American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc.  2023;71(7):2052-2081. doi:10.1111/jgs.18372. Link U.S. Food and Drug Administration. FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. 2018. Available at: Link . Kuehn BM. FDA warns about using antipsychotic drugs for dementia. JAMA.  2005;293(20):2462. doi:10.1001/jama.293.20.2462. Link U.S. Food and Drug Administration. Boxed warning for increased mortality in elderly patients with dementia-related psychosis. 2020. Available at: Link . Billioti de Gage S, Moride Y, Bégaud B, et al. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ.  2014;349:g5205. doi:10.1136/bmj.g5205. Link Joyce G, et al. Benzodiazepine use and the risk of dementia: a causal analysis. Ther Adv Drug Saf.  2022;13:20420986221091775. doi:10.1177/20420986221091775. Link Guo F, et al. Association between Z-drug use and risk of cognitive impairment in middle-aged and older patients with chronic insomnia. Front Neurol.  2021;12:721943. doi:10.3389/fneur.2021.721943. Link Swart LM, van der Zanden V, Spies PE, de Rooij SE, van Munster BC. The comparative risk of delirium with different opioids: a systematic review. Drugs Aging.  2017;34(6):437-443. doi:10.1007/s40266-017-0455-y. Link Neelamegam M, Yee A, Wan YH, Chin MC. The effect of opioids on the cognitive function of older adults: a systematic review. Ann Geriatr Med Res.  2021;25(4):243-256. doi:10.4235/agmr.21.0089. Link Mula M, Trimble MR. Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors. Ther Adv Neurol Disord.  2012;5(5):273-282. doi:10.1177/1756285612455034. Link Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc.  2006;81(10):1361-1367. doi:10.4065/81.10.1361. Link Chazot PL, Wainwright CL, Thompson CL. Histamine and delirium: current opinion. Front Pharmacol.  2019;10:299. doi:10.3389/fphar.2019.00299. Link Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

Your Insulin Level May be Dangerously High, Even if Your Blood Sugar is "Normal" Why Lowering Insulin Matters: Inflammation, Cancer Risk, and Insulin Resistance—What the General Public Should Know Most of us recognize insulin as the hormone that helps move glucose from the blood into our cells. Less widely appreciated is the fact that persistently  elevated insulin—often called hyperinsulinemia —is not benign. It is part of a broader metabolic picture that fuels chronic, “smoldering” inflammation, accelerates insulin resistance, and is epidemiologically linked with higher risks for several cancers. The encouraging news is that everyday choices—what we eat, how we move, how we sleep—can lower insulin levels and shift that biology in our favor. This essay lays out, in plain language, why insulin matters and how to act on it—grounded in clinical and mechanistic research. In short, the insulin level, the greater the harm. Insulin: more than a blood-sugar hormone Insulin is a powerful growth  and storage  signal. In the right context—after a meal—it helps muscles and the liver absorb glucose, promotes glycogen storage, and tempers the liver’s own glucose output. When insulin is chronically elevated , however, tissues become less responsive (insulin resistance), the pancreas compensates by producing even more insulin, and a self‐reinforcing cycle develops. Over time, that cycle intertwines with inflammatory pathways and adverse cell-growth signals. Reviews over the last decade synthesize evidence that hyperinsulinemia is implicated in metabolic inflammation, aging biology, and cancer-promoting processes. E-DMJ PMC How high insulin promotes inflammation (“metaflammation”) Excess energy intake—especially ultra-processed foods rich in refined starches and sugars—promotes fat storage in adipose tissue. As fat cells enlarge, they release danger signals and attract immune cells (particularly macrophages). Those immune cells and stressed adipocytes secrete cytokines like TNF-α , IL-6 , and MCP-1 , which activate inflammatory cascades (NF-κB, JNK). The result is chronic low-grade inflammation  that further impairs insulin signaling in liver, muscle, and fat, raising insulin levels still more. This bidirectional loop—sometimes called metaflammation —is now a central model for obesity-related insulin resistance. Nature+1 PMC Clinically, you can sometimes “see” the loop using simple markers. Waist circumference tracks visceral adiposity; high triglycerides with low HDL suggest hepatic insulin resistance; high-sensitivity CRP (hs-CRP) is one marker of systemic inflammation. While no single test tells the whole story, the pattern often points to the same biology. The insulin–IGF axis and cancer risk: association, mechanism, and nuance. Lower insulin levels reduce cancer risk. Cancer risk and progression are influenced by many factors, but one repeatedly observed theme is the insulin/IGF-1 axis . Insulin and insulin-like growth factors activate PI3K–AKT–mTOR and MAPK pathways that promote cell survival and proliferation; chronically elevated signaling may create a more permissive environment for tumor initiation and growth. Epidemiologic studies link higher fasting insulin or C-peptide  (a proxy for endogenous insulin secretion) with greater risk of colorectal and certain endocrine-related cancers, and diabetes itself is associated with increased colorectal cancer risk. Mechanistic reviews and large observational syntheses converge on this axis as biologically plausible and clinically relevant, though causality and effect sizes vary by tumor type and study design. PMC+1 PubMed The prudent takeaway is not that insulin “causes” cancer in a simple linear way, but that metabolic health—lower fasting insulin, less visceral adiposity, improved insulin sensitivity—likely shifts risk in the right direction. Not all 'health foods' are very healthy, at all Practical ways to lower insulin and calm inflammation 1) Choose a dietary pattern that blunts insulin spikes— and  is sustainable Two broad strategies consistently help: Mediterranean-style eating.  High in vegetables, legumes, nuts, fish, olive oil, and minimally processed whole grains, this pattern is associated with lower insulin resistance and improved cardiometabolic markers—independent of weight loss. Recent syntheses show better HOMA-IR and post-challenge insulin sensitivity with higher adherence. PMC BioMed Central Lower glycemic load (GL) approaches.  Emphasizing fiber-rich carbohydrates, intact whole grains, legumes, and reduced refined starch/sugar leads to smaller post-meal glucose and insulin excursions. A large evidence review suggests low-GI/GL dietary patterns produce modest but meaningful improvements in glycemic control, lipids, blood pressure, adiposity, and inflammation—particularly in people with diabetes. PMC No single macronutrient ratio fits everyone, and trials differ on whether lowering glycemic index/load independently reduces inflammatory cytokines. That said, prioritizing fiber-rich, minimally processed foods is a robust, pragmatic way to reduce both insulin demand and inflammatory tone. PubMed A word on intermittent fasting (IF) and time-restricted eating (TRE).  IF can lower fasting insulin and improve insulin sensitivity for many people, in part by extending periods of low insulin (“metabolic switching”). A major review and randomized trials—especially early time-restricted feeding—support improvements in insulin sensitivity and related risk markers. However, IF is not universally superior to other calorie-controlled approaches; the “best” method is the one you can sustain safely. New England Journal of Medicine Nature Fiber is your friend.  Soluble fiber slows glucose absorption, feeds the gut microbiome, and yields short-chain fatty acids that improve insulin signaling and inflammatory tone. Recent reviews and trials show that higher fiber intake—particularly from whole foods—supports insulin sensitivity and glycemic control. MDPI 2) Move your body—consistently Regular physical activity is a potent insulin sensitizer. Meta-analytic data show that aerobic  and combined  (aerobic + resistance) programs lower fasting insulin and HOMA-IR; resistance-only programs can still help (especially for muscle mass and glucose disposal), but combined training generally produces the most reliable improvements in insulin biology. Aim for at least 150–300 minutes/week of moderate aerobic activity plus 2–3 sessions/week of resistance training. PMC 3) Lose a little (or a lot) of visceral fat Even 5–10% weight loss  can substantially reduce fasting insulin and inflammation, with larger losses (when appropriate and safe) yielding larger metabolic dividends. In people with prediabetes, an intensive lifestyle program targeting ~7% weight loss and regular activity cut progression to type 2 diabetes by 58%  over ~3 years—far outperforming metformin in that trial—underscoring how strongly lifestyle affects insulin resistance risk. New England Journal of Medicine 4) Sleep like it’s your job Short or disrupted sleep impairs insulin signaling after just a night or two, and chronic sleep curtailment promotes weight gain and insulin resistance via appetite hormones and sympathetic activation. Guarding 7–9 hours of regular, high-quality sleep is a practical, under-appreciated insulin-lowering intervention. The Lancet 5) Tame chronic stress Psychophysiologic stress raises counter-regulatory hormones (cortisol, catecholamines) that antagonize insulin. Mind-body practices, social connection, and exposure to daylight and nature are not mere niceties; they alter autonomic tone and can lower cardiometabolic risk over time. (Pair this with the sleep guidance above for compounding benefits.) How (and whether) to measure insulin Glucose-centric tests (fasting glucose, oral glucose tolerance, HbA1c) are standard. Fasting insulin  and HOMA-IR  can add context, especially in earlier stages when glucose still looks “normal.” C-peptide  sometimes helps when teasing out endogenous insulin production (e.g., differentiating pancreatic reserve in diabetes phenotypes) and has been used in research on cancer risk, but it’s not a routine cancer screen. Discuss with your clinician which tests, if any, will change management for you personally. In my practice, I check insulin levels simultaneously with glucose and HgA1c. By doing this, I get a good view into past metabolic activity with the HgA1c, present situation with the blood glucose, and future issues with the Insulin level. Safety and special situations If you’re on glucose-lowering medications (especially insulin or sulfonylureas), dietary shifts and fasting protocols require medical supervision  to avoid hypoglycemia. People with eating disorders, frailty, pregnancy, or certain endocrine conditions need tailored plans. For many, the safest and most sustainable first steps are Mediterranean-style meals, more daily movement, better sleep, and stress hygiene. A pragmatic 6-week blueprint Plate pattern at each meal:  half non-starchy vegetables; a palm-sized portion of protein; a thumb-sized portion of healthy fat; and a fist-sized portion of intact, fiber-rich carbs (or fruit). Fiber target:  work toward ≥30–40 g/day from legumes, vegetables, whole grains, nuts, seeds, and fruit. Glycemic load swaps:  replace refined grains and sugary beverages with water/tea/coffee (minimal sweetener), steel-cut oats or barley, intact brown rice or quinoa, lentils/beans. PMC Movement “minimum viable dose”:  30 minutes brisk walking most days + two short resistance sessions (push-pull-legs basics). PMC Sleep routine:  fixed sleep/wake times, dim evening light, cool/dark bedroom, morning daylight. The Lancet Optional TRE trial:  consider a 10–12-hour eating window (e.g., 8 am–6 pm) for 3–4 weeks; avoid aggressive fasting if you use insulin/secretagogues or have a history of disordered eating. Nature Track what matters:  waist circumference, fasting triglycerides/HDL ratio, and—if appropriate—fasting insulin or HOMA-IR with your clinician every few months. Vitamins, Minerals and other Supplements: These will be covered in subsequent Blogs . Bottom line Lowering chronically elevated insulin is not about chasing a number; it is about changing the terrain  in which inflammation and insulin resistance take root—and where cancer-promoting signals can gain a foothold. Nutrient-dense, lower-GL eating; fiber; consistent movement; adequate sleep; and stress control are the most durable levers we have. They are also the least expensive and the most broadly beneficial across chronic disease domains. References Zhang AMY, et al. Hyperinsulinemia in Obesity, Inflammation, and Cancer.   Diabetes Metab J.  2021. doi:10.4093/dmj.2020.0250. E-DMJ Szablewski L. Insulin Resistance: The Increased Risk of Cancers.   Int J Mol Sci.  2024. (Open access.) PMC Li M, et al. Trends in insulin resistance: insights into mechanisms and therapeutics.   Signal Transduct Target Ther.  2022. Nature Guria S, et al. Adipose tissue macrophages and their role in obesity-induced inflammation and insulin resistance.   Front Endocrinol.  2023. PMC Sethi JK, et al. Metabolic Messengers: tumour necrosis factor (TNF).   Nat Metab.  2021. Nature Yu GH, et al. Diabetes and Colorectal Cancer Risk.   Cancers (Basel).  2022. PMC Chen L, et al. Circulating C-peptide level is a predictive factor for colorectal neoplasia.   J Gastroenterol Hepatol.  2013 (meta-analysis). PubMed Zhong W, et al. Obesity and endocrine-related cancer: the important role of the IGF system.   Front Endocrinol.  2023. PMC de Cabo R, Mattson MP. Effects of Intermittent Fasting on Health, Aging, and Disease.   N Engl J Med.  2019. New England Journal of Medicine Xie Z, et al. Randomized controlled trial of early time-restricted feeding: improvements in insulin sensitivity and inflammatory markers.   Nat Commun.  2022. Nature Kazeminasab F, et al. Effects of exercise training on insulin resistance: meta-analysis.   BMC Endocr Disord.  2023. PMC Vetrani C, et al. Mediterranean diet adherence and insulin resistance in overweight/obesity.   Nutrients.  2023. PMC Zheng X, et al. Mediterranean diet and cardiometabolic risk: meta-analysis.   BMC Nutr.  2024. BioMed Central Chiavaroli L, et al. Low-GI/GL dietary patterns: effects on glycemic control, lipids, BP, adiposity, and inflammation.   BMJ  (systematic review/meta-analysis), 2021. PMC Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin.   N Engl J Med.  2002. New England Journal of Medicine Subscribe to our Blog   Youtube Channel Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

Room Temperature is extremely important in obtaining a good sleep As a physician, I often remind patients that sleep is not just a passive state; it is an active, restorative process essential for health. While many people focus on bedtime routines, caffeine intake, or screen use before bed, fewer realize how profoundly bedroom temperature  can influence sleep quality. Why Temperature Matters in Sleep The human body follows a natural circadian rhythm , which regulates sleep and wake cycles. A key part of this rhythm is the drop in core body temperature  that occurs at night. This cooling signals the brain that it is time to sleep. If the sleep environment is too warm or too cold, it can disrupt this natural process, leading to fragmented sleep or difficulty falling asleep. The Optimal Temperature Range Research suggests that the ideal bedroom temperature for most adults is between 60°F and 67°F (15.5°C–19.5°C) . Within this range, the body can best maintain the slight drop in core temperature necessary for deep, restorative sleep. Temperatures above 70°F (21°C) are associated with more nighttime awakenings, while excessively cold environments can also lead to discomfort and poor sleep. Physiological Basis During sleep onset, blood vessels in the hands, feet, and face dilate to release heat, lowering core body temperature. A cooler environment assists this process. By contrast, a hot room impairs heat dissipation, prolonging sleep latency (the time it takes to fall asleep) and reducing slow-wave and REM sleep. Cold environments may stimulate shivering, which interferes with sleep continuity. Individual Variation The “optimal” temperature can vary based on: Age : Infants and older adults may need slightly warmer environments. Sex and hormones : Women may experience different thermal comfort during menstrual cycles or menopause. Medical conditions : Disorders such as insomnia, sleep apnea, or neuropathy may make individuals more sensitive to thermal stress. Practical Steps for Better Sleep Temperature Set your thermostat : Aim for 60–67°F for adults; 65–70°F for infants and older adults. Bedding choice : Use breathable materials like cotton or bamboo. Avoid heavy blankets in warm weather. Pajamas : Wear lightweight, breathable fabrics to aid heat dissipation. Mattresses and pillows : Cooling gels or ventilated foam can help regulate body heat. Air circulation : Fans and open windows can enhance comfort, especially in humid climates. Warm baths before bed : Surprisingly, a warm bath helps sleep by causing rebound cooling once you get out. Broader Health Implications Maintaining an optimal sleep temperature doesn’t just improve rest—it supports metabolic health, cognitive performance, and emotional regulation. Poor sleep temperature control has been linked to insomnia, cardiovascular strain, and reduced daytime alertness. Conclusion Sleep is one of the most powerful tools we have for health. By keeping your bedroom in the 60–67°F range , you give your body the environment it needs to achieve restorative rest. Simple adjustments to your room’s temperature, bedding, and clothing can lead to profound improvements in sleep quality and overall well-being. Understanding that changing habits is difficult, my general recommendation is to drop the bedroom temperature to 71 degrees, sleep under your blanket, and get used to this temperature. If you begin to sleep better, this may be all you need to do. If you need to drop the temperture below 71 degrees, decrease by 1 degree ever few days until you get to 67 degrees, and then maintain the temperature. References Okamoto-Mizuno K, Mizuno K. Effects of thermal environment on sleep and circadian rhythm. J Physiol Anthropol.  2012;31(1):14. Harding EC, Franks NP, Wisden W. Sleep and thermoregulation. Curr Opin Physiol.  2019;15:7-13. Czeisler CA, et al. Human sleep: its duration and organization depend on its circadian phase. Science.  1980;210(4475):1264-1267. Krauchi K, Deboer T. The interrelationship between sleep regulation and thermoregulation. Front Biosci.  2010;15:604-625. Lan L, Lian Z, Pan L, Ye Q. Neurobehavioral approach for evaluation of office workers’ productivity: the effects of room temperature. Build Environ.  2009;44(8):1578-1588. van Marken Lichtenbelt WD, et al. Cold exposure—a tool to increase energy expenditure in humans. Trends Endocrinol Metab.  2014;25(4):165-167. Raymann RJEM, et al. Skin deep: local heat application increases sleep depth. Sleep.  2008;31(2):191-199. Okamoto-Mizuno K, et al. Effects of humid heat exposure on human sleep stages and body temperature. Sleep.  2004;27(3):420-426. Dautovich ND, et al. Sleep and temperature regulation in aging. Handb Clin Neurol.  2019;167:499-511. Lan L, Lian Z, Lin Y. Comfortably cool bedroom environment facilitates deeper sleep. Build Environ.  2016;103:208-216. Krauchi K, Cajochen C. Body temperatures, sleepiness, and melatonin in young and elderly humans during day and night. J Biol Rhythms.  1997;12(6): 536-546. Link Romanovsky AA. Thermoregulation: some concepts have changed. Functional architecture of the thermoregulatory system.   Am J Physiol Regul Integr Comp Physiol.  2007;292(1):R37-R46. Link Harding EC, et al. The temperature dependence of sleep. Curr Biol.  2018;28(21):3596-3604. Link Magnavita N, et al. Sleep problems and workplace comfort in healthcare workers. Int J Environ Res Public Health.  2018;15(9):1975. Link Badia P, et al. Bright light and body temperature: independent and interactive effects on human sleep. Am J Physiol.  1991;260(3 Pt 2):R422-R430. Link Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

As a physician, I often see patients who struggle with foot pain, especially in the heel. One of the most common culprits is plantar fasciitis , a condition that affects people of all ages but is especially noticeable among those who are on their feet a lot, athletes, and individuals with certain risk factors. Let’s break down what it is, what causes it, how it’s treated, and—most importantly—how you can prevent it. The Plantar Fascia is a tough band of muscles and tendons on the bottom (Plantar Aspect) of the Foot What Is Plantar Fasciitis and Why does it Cause Foot Pain? The plantar fascia  is a thick band of tissue that runs along the bottom of your foot, connecting your heel bone to your toes. Its job is to support the arch of your foot and absorb shock when you walk or run. When this tissue becomes irritated or inflamed, it leads to plantar fasciitis. The hallmark symptom is sharp heel and foot pain , especially when taking the first steps in the morning or after sitting for a while. The plantar fascia is a tough band of tissue that stretches from the forefoot to the heel, and is responsible for maintenance of arch integrity. Causes and Risk Factors Plantar fasciitis usually develops from repeated stress  on the plantar fascia. Several factors increase the likelihood of developing it: Foot mechanics : Flat feet, high arches, or an abnormal walking pattern can place extra stress on the fascia. Overuse : Long-distance running, dancing, or prolonged standing can strain the heel. Improper footwear : Shoes without proper arch support or cushioning can worsen the problem. Age and weight : It’s more common in people between ages 40–60 and in those carrying excess weight, which increases pressure on the fore-foot. The Plantar Fascia is under maximal tension when weight is on the forefoot. Due to persistent mechanical stress resulting from prolonged walking, standing and stretching, the plantar fascia withstands remarkable mechanical challenges during routine activity.  As a result of microtrauma subsequent to jumping, jogging, and running, the plantar fascia can develop  small areas where it is torn from the attachment on the heel. Foot and Hell Pain are a direct result. Symptoms The classic sign is a sharp, stabbing pain at the bottom of the heel . The pain is usually worse in the morning or after periods of rest, but may improve with movement. Over time, the discomfort can become constant if untreated. The pain of plantar fasciitis is usually  stabbing or burning pain in nature,  usually worse in the morning.   The pain seems to be worse when your feet hit the floor after sleep, and the pain eases with motion and mobility. The pain will come and go, worse with certain types of shoes and with pressure on localized areas. Treatment Options The good news is that most cases of plantar fasciitis improve with conservative treatment : Rest and activity modification : Reducing high-impact activities gives the fascia time to heal. Ice and anti-inflammatory measures : Applying ice or taking non-steroidal anti-inflammatory drugs (NSAIDs) can reduce pain and swelling. Stretching and physical therapy : Gentle calf stretches, plantar fascia stretches, and strengthening exercises for the foot and ankle can help. Supportive footwear and orthotics : Shoes with good arch support, cushioned soles, or custom orthotic inserts take stress off the fascia. Night splints : Wearing a splint that keeps the foot flexed overnight can stretch the fascia and lessen morning pain. In more severe or persistent cases, other treatments such as steroid injections, shockwave therapy, or surgery  may be considered, but these are reserved for people who do not respond to conservative measures. Prevention Strategies Preventing plantar fasciitis often comes down to protecting your feet from stress : Wear shoes with good cushioning and arch support. Replace athletic shoes regularly, especially if you run or walk often. Stretch your calves and feet before and after exercise. Maintain a healthy weight to reduce pressure on your feet. Avoid walking barefoot on hard surfaces for prolonged periods. Final Thoughts Plantar fasciitis can be frustrating, but with the right approach, it is manageable and often curable without invasive treatment. By paying attention to your footwear, body mechanics, and activity habits, you can both recover from plantar fasciitis and reduce the risk of it coming back. References Buchbinder R. Plantar fasciitis. N Engl J Med.  2004;350(21):2159-2166. Riddle DL, Schappert SM. Volume of ambulatory care visits and patterns of care for patients diagnosed with plantar fasciitis. Foot Ankle Int.  2004;25(5):303-310. League AC. Current concepts review: plantar fasciitis. Foot Ankle Int.  2008;29(3):358-366. Cutts S, Obi N, Pasapula C, Chan W. Plantar fasciitis. Ann R Coll Surg Engl.  2012;94(8):539-542. Martin RL, Irrgang JJ, Conti SF. Outcome study of subjects with insertional plantar fasciitis. Foot Ankle Int.  1998;19(12):803-811. Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

When is abdominal pain an emergency? Abdominal pain can be unsettling at any stage of life. Many causes are harmless, but some need urgent care. This post explains when to worry about abdominal pain and when to see a doctor . It follows an evidence-based approach and uses insights from reputable medical sources. Understanding Abdominal Pain Abdominal pain  is any discomfort felt anywhere between the chest and groin. Because the abdomen contains many organs, pain can come from the digestive system, muscles or even organs outside the belly. The severity does not always match the seriousness of a chronic condition and may pass or persist depending upon the cause. Types of Abdominal Pain: Acute vs. Chronic Acute abdominal pain starts suddenly and lasts hours or days. Causes  range from infections to injuries.  Chronic pain that persists for weeks or longer and is often due to underlying conditions such as irritable bowel syndrome or ulcers. Persistent abdominal pain always warrants medical evaluation. Menstrual cramps can be mild or severe, and may require medical attention if persistent or intense. Common Causes of Abdominal Pain Digestive issues:  Gas, indigestion, constipation and diarrhea often cause temporary pain. Eating too quickly, food poisoning, or food intolerances may also lead to discomfort. Inflammation: Infections like viral gastroenteritis, peptic ulcers, or urinary tract infections can cause inflammatory pain. Female reproductive cycle:  Menstrual cramps and ovulation pain are common sources of lower abdominal discomfort. Other organs:  Problems in the chest (heart attack), pelvis, or back can mimic stomach pain.  When to Worry About Abdominal Pain Most bellyaches resolve with time, but certain features suggest  a more serious issue . Pay attention to the duration and severity of pain and any accompanying symptoms. Pain That Persists or Worsens Unexplained abdominal pain that is persistent or severe requires medical attention . If the pain follows trauma, occurs during pregnancy or in young children, seek prompt evaluation.  Persistent pain after surgery or in older adults may indicate bowel obstruction or another complication. It is always best to seek medical attention if there is any question of urgency or emergency When To See A Doctor About Abdominal Pain Seek a doctor’s assistance immediately if abdominal pain is accompanied by: Fever: Persistent fever can signal infection or inflammation. Nausea or vomiting: Continuous nausea or vomiting, especially with inability to keep liquids down, is a red flag. Blood in stool, urine or vomit:  Blood can indicate bleeding in the gastrointestinal tract. Jaundice:  Yellowing of the skin and eyes may suggest liver or gallbladder disease. Swelling and tenderness: A swollen or tender abdomen requires evaluation. Shortness of breath or chest pressure: Pain associated with difficulty breathing or chest pain could reflect heart or lung problems. Inability to pass gas or stool: Bloating, constipation, and an inability to pass gas can signal bowel obstruction When Is Abdominal Pain an Emergency? Some situations demand immediate emergency care. Recognizing these signs can be lifesaving. Signs You Should Go to the ER Immediately According to the Mayo Clinic , you should call emergency services if your abdominal pain is severe and accompanied by trauma, chest pressure, or pain.  Nurse evaluating an ER patient with abdominal pain. Go to the emergency department if you experience: Severe, sudden pain:  A sudden onset of intense pain that makes movement difficult is concerning. Pain with fever or chills : Fever may point to infection or inflammation. Persistent pain in the lower right abdomen: This may indicate appendicitis. Chest pressure or shortness of breath:  Pain radiating to the chest, shoulder, or back can mimic heart attack. Pain with bloody vomiting or black stools: These signs suggest internal bleeding. Bloating with inability to pass gas or stool: Could be a bowel obstruction. Conditions That Require Urgent Care Several conditions necessitate urgent evaluation . Appendicitis Pain  often begins near the belly button and migrates to the lower right abdomen. It may start slowly and worsen over 12-24 hours.  Appendicitis is more common in teenagers and young adults. Bowel Obstruction Bloating, constipation and inability to pass gas, especially in people with previous abdominal surgery, suggest obstruction. Acute Pancreatitis Pain starts in the upper abdomen and worsens after eating. Symptoms may include fever and rapid pulse. Kidney Stones Sharp, cramping pain in the lower abdomen or back that peaks rapidly, often early in the morning, could signal kidney stones. Gallbladder Infection Severe right upper quadrant pain with fever and jaundice may indicate cholecystitis . Not All Abdominal Pain Requires An Emergency Room Visit.  Your primary care doctor can evaluate many conditions and decide if specialist care is needed. Schedule a doctor's visit if your pain lasts more than a few days or if it worries you.  Seek care sooner if you have underlying medical problems or are older, pregnant, or immunocompromised. What Your Primary Care Provider Can Help With Your doctor can diagnose and treat conditions like indigestion, constipation, food intolerance, or mild infections.  They may prescribe medication, recommend lifestyle changes, or order basic tests. If you have chronic conditions such as irritable bowel syndrome, your doctor can help manage symptoms and refer you to a specialist if needed. When to Ask for a Specialist Referral You might need a gastroenterologist  or surgeon if your symptoms are persistent, unexplained, or linked to structural issues.  Conditions like inflammatory bowel disease, gallstones, or hernias often require specialist evaluation. Recurrent pain in older adults may call for imaging studies to rule out cancer or vascular problems. Diagnostic tests for abdominal pain can range from blood tests to ultrasound imaging. What to Expect During a Medical Evaluation Questions You'll Be Asked Health professionals will ask about the location, intensity, and duration of your pain. They may inquire about your diet, bowel habits, and any triggers or relieving factors.  Possible Tests or Imaging Your doctor may perform blood tests , urine tests or stool studies.  Imaging like ultrasound or CT scans can reveal gallstones, appendicitis or other structural problems. Endoscopy may be used to examine the stomach or intestines.  The tests ordered depend on your symptoms, age and medical history. How to Track Your Symptoms at Home A symptom diary can provide valuable insight. Be sure to include: Time: Record when the pain occurs and how long it lasts. Location:  Note where you feel pain and whether it spreads. Severity:  Use a scale from 0 to 10 to rate intensity. Triggers or relief: Track foods, activities, or bowel habits that affect pain and any medications that help. Final Thoughts On When Should You Worry About Abdominal Pain Abdominal pain  is a common complaint across all ages.  Most cases are minor, but persistent or severe pain or pain with concerning symptoms should prompt a medical evaluation.  Understanding when abdominal pain is an emergency helps you act quickly and reduces the risk of complications. Listen to your body and seek care when something feels wrong.  At Longwood, Florida-based Stages of Life Medical Institute , our pain specialists diagnose all forms of abdominal pain and help guide appropriate treatment.  To become a new patient, simply click her e. Subscribe to our Blog   Youtube Channel Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

A different kind of Weight Management. Prevention of Dementia and Diabetes Audience:  patients and families curious about whether GLP-1–based medicines (e.g., semaglutide, tirzepatide, liraglutide) might help protect brain health—especially given growing discussion of Alzheimer’s disease as “type 3 diabetes.” The takeaway up front As a physician, I see two parallel truths emerging from recent science. First, Alzheimer’s disease and other dementias are strongly linked to metabolic dysfunction—especially insulin resistance in the brain, sometimes labeled “type 3 diabetes.”  Second, a class of diabetes and weight-management medicines called GLP-1 receptor agonists (GLP-1 RAs)  shows early but increasingly consistent signals that they may lower dementia risk in people with type 2 diabetes, and possibly slow specific biological changes of Alzheimer’s in small clinical trials. These signals are not yet the same as definitive proof of prevention, but they are promising enough to merit discussion with your clinician if you’re already a candidate for these drugs for diabetes, obesity, or cardiometabolic risk. JAMA Network+3MDPI+3ScienceDirect+3 Why Alzheimer’s has been called “type 3 diabetes” For more than a decade, researchers have observed that insulin signaling in the brain  is impaired in Alzheimer’s disease (AD). Insulin helps neurons use glucose, modulates synapses (the “wiring” that underlies memory), and dampens inflammatory cascades. When brain insulin signaling falters, glucose metabolism drops, oxidative stress rises, amyloid and tau processing can worsen, and microglia (the brain’s immune cells) are more likely to stay in an inflammatory state. These patterns have led many scientists to frame AD as a brain-specific insulin-resistant state , colloquially “type 3 diabetes.” While not every expert embraces the term, multiple recent reviews detail the mechanistic links. MDPI+2ScienceDirect+2 Enter GLP-1: from pancreas to brain GLP-1  is a hormone made in the gut and the brain that boosts insulin secretion when glucose is high, tempers glucagon, slows gastric emptying, and promotes satiety. GLP-1 receptor agonists (GLP-1 RAs)  are long-acting versions of this signal (liraglutide, semaglutide, dulaglutide, and the dual GIP/GLP-1 agent tirzepatide) developed to treat type 2 diabetes and, more recently, obesity. Beyond glucose and weight, GLP-1 signaling appears to modulate neuroinflammation, improve neuronal energy handling, and support vascular health , all relevant to neurodegeneration. Nature+2PMC+2 Do these medicines reach the brain? Evidence suggests that GLP-1 pathways influence the central nervous system via multiple routes: some agents and/or their downstream effects reach or affect the brain and blood–brain barrier , altering glucose transport, microglial activation, and synaptic function in preclinical and early human studies. Quantitative BBB penetration differs by molecule and remains an active research area. PMC+1 What the human data show so far. Why GLP-1 agents, like Zepbound, help with sleep apnea, diabetes, heart disease, and weight loss 1) Large real-world observational studies (association ≠ proof) In 2025, a Nature Medicine  analysis of >2 million U.S. veterans with diabetes mapped outcomes after initiating GLP-1 RAs vs several comparators. Among many findings, GLP-1 use was associated with lower risk of Alzheimer’s disease  and other neurological outcomes compared with usual care, with effect sizes varying by comparator drug class. Observational designs can’t prove causality, but the signal aligns with growing literature. PubMed A JAMA Network Open  cohort (60,860 adults with type 2 diabetes and obesity) reported that semaglutide or tirzepatide  users had lower risks of dementia, stroke, and all-cause mortality  than patients treated with other glucose-lowering drugs. Again, this is association, not proof, but it’s consistent and clinically meaningful. JAMA Network Several complementary analyses—including the largest direct comparison of GLP-1 RAs vs metformin  as initial therapy—suggest GLP-1 drugs may reduce overall and Alzheimer’s-type dementias  more than metformin in people with type 2 diabetes. These studies use modern matching methods but remain observational. BMJ Disease Reviews Finally, a systematic review and meta-analysis in JAMA Neurology (2025)  pooling randomized cardiometabolic trials found no overall cognitive/dementia benefit across all cardioprotective diabetes drugs , but GLP-1 RAs stood out with a statistically significant reduction in incident dementia  in subgroup analyses—important but still Can GLP-1 Drugs Help Prevent Dementia? A Physician Explains GLP-1 Medications help with both diabetes and obesity while preventing neuronal damage resulting in Dementia You may have heard the terms GLP-1 agents, Alzheimer’s, dementia, “type 3 diabetes”—wondered how they connect, and whether drugs designed for diabetes (or weight loss) might also protect your brain. Here's what I, as a physician, see in the current scientific landscape. I’ll try to be optimistic where the data warrant it, but also clear about what remains uncertain. Background: Dementia, Alzheimer’s & “Type 3 Diabetes” Insulin Resistance of Diabetes type III Dementia—especially Alzheimer’s disease (AD)—is a progressive decline in cognition, memory, planning, and daily functioning. Currently, there is no cure, though some medications slow progression in select patients. Prevention, or delaying onset, is thus a major clinical goal. “Type 3 diabetes”  is a term used to underscore a growing body of evidence that Alzheimer’s involves insulin resistance in the brain, impaired glucose metabolism, mitochondrial dysfunction, chronic inflammation, and oxidative stress—much like in type 2 diabetes. The idea is not  that Alzheimer’s is literally the same as type 2 diabetes, but that many pathological features overlap. ScienceDirect+3MDPI+3PMC+3 Key points: The brain uses glucose as its primary fuel. If insulin signaling is disrupted, neurons may suffer energy deficits. Insulin has roles in synaptic plasticity, modulating tau phosphorylation, amyloid metabolism, and reducing oxidative stress. PMC+3Frontiers+3Diabetes Journals+3 People with type 2 diabetes (T2DM) have significantly increased risk of AD/dementia. MDPI+2PMC+2 Thus, any intervention that improves insulin sensitivity, reduces inflammation, supports mitochondrial health, and perhaps modulates amyloid/tau pathology has theoretical potential in dementia prevention. What Are GLP-1 Agents? GLP -1 Agents affect much more than appetite and weight GLP-1 (glucagon-like peptide‐1) is a hormone made in the gut (and to some extent in the brain) that helps with: stimulating insulin secretion when glucose is high; suppressing glucagon; slowing gastric emptying; promoting satiety; and possibly having direct effects in other organs (heart, brain, immune system). GLP-1 receptor agonists (GLP-1 RAs) are medications modeled on this hormone (or its effects). They are used in T2DM, obesity, and increasingly in cardiovascular risk reduction. Examples: liraglutide, semaglutide, dulaglutide, occasionally dual agents (GLP-1 + GIP like tirzepatide). These agents have multiple effects relevant to brain health: improved glycemic control (lowering glucose spikes, avoiding hyperglycemia) weight loss, which reduces many risk factors (vascular disease, hypertension, dyslipidemia) possible reduction of systemic inflammation possible direct neural effects: crossing—or affecting—the blood brain barrier; reducing amyloid and tau pathology; improving neuronal insulin signaling; preserving mitochondrial function; reducing oxidative stress. Frontiers+2PMC+2 Mechanistic and Animal Evidence Before we look at clinical data, the animal and in vitro work is reassuring—and helps suggest how  GLP-1 might work in the brain. Amyloid & tau modulation : In mouse models of AD, GLP-1 RAs reduce amyloid β oligomer levels and plaque load; reduce tau hyperphosphorylation. Diabetes Journals+1 Neuroinflammation / oxidative stress : GLP-1 agents appear to reduce microglial activation, lower inflammatory cytokines, improve antioxidant defenses in brain tissue. Frontiers+2PMC+2 Mitochondrial health and neuronal energy : Some studies show improved mitochondrial function, decreased dysfunction, improved neuronal metabolic reprogramming in response to insulin resistance when GLP-1 pathways are engaged. BioMed Central+1 Brain insulin signaling : GLP-1 RAs in animal models can improve insulin signaling in neurons, enhancing glucose uptake and utilization in brain regions affected in AD. PMC+1 So mechanistically, there is  plausibility. Animal studies are consistent across multiple models. But as always, animal studies are not enough to guarantee human benefits. Human / Clinical Evidence: What We Know Now we move from what could  happen, to what seems  to happen in people. Observational Studies & Real‐World Data These are large database studies, often with millions of patients, comparing dementia incidence (or cognitive decline) among people with T2DM (or obesity) using GLP-1 RAs vs other therapies. A recent JAMA article showed that among people with T2DM, use of GLP-1 RAs was associated with a statistically significant decrease in dementia risk compared with other antidiabetic drugs. JAMA Network Another large observational study found that people with T2DM and obesity using semaglutide or tirzepatide had lower risk of dementia, stroke, and all-cause mortality compared to those on other glucose‐lowering agents. Alzheimer's & Dementia Journals+2The Lancet+2 A meta-analysis pooling many clinical trials (though mostly for diabetes endpoints) suggested that GLP-1 RAs (versus placebo or other drugs) may reduce risk of dementia among diabetics. The Lancet+1 Pros of observational data: large numbers, real world; cons: possible confounding (people who are prescribed GLP-1 agents may differ in many ways), reverse causality, indication bias, duration of follow-up may be short for dementia (often slow developing). Randomized Trials & Clinical Interventions These are more limited so far, but growing. The ELAD trial  (Evaluating the Effects of the Novel GLP-1 Analogue Liraglutide in Alzheimer’s Disease) was a Phase 2b randomized, double-blind, placebo-controlled study in ~204 patients with mild AD. Over one year, liraglutide did not  significantly improve the primary endpoint (change in cerebral glucose metabolic rate in certain brain regions), but secondary endpoints—including brain volume loss, and cognitive measures—showed benefit: ~50% less loss in several brain regions compared to placebo; also slower decline on cognitive tests. AAIC 2026 A comparative effectiveness analysis of second-line diabetes medications in real‐world registry (Danish registry) comparing GLP-1 RAs to other agents found a protective effect of GLP-1 RAs vs certain other second-line drugs over 5 years, though not against all  comparators. arXiv Systematic Reviews / Meta-analyses A recent systematic review on “type 3 diabetes” draws together evidence of overlapping mechanistic pathways, supporting the idea that agents targeting insulin resistance (including GLP-1 RAs) might have benefit. PMC+2PMC+2 Another meta-analysis (in JAMA Neurology) pooling more than 160,000 participants across many trials of glucose-lowering agents found that GLP-1 drugs were among the few classes associated with reductions in Alzheimer’s disease and other dementias in subgroup analyses. alzinfo.org +1 Putting It Together: What It Might Mean for You As your physician, here's how I think about this evidence, and how it might apply in your case. Potential Benefits (What We Can Hope For) Slowing or delaying onset of dementia , especially in people with risk factors: T2DM, obesity, metabolic syndrome, hypertension. If GLP-1 agents reduce incidence (as observational studies suggest), that may translate into clinically meaningful delay. Preserving brain structure and function , as suggested by trials like ELAD: less loss of brain volume, possibly less cognitive decline, at least in early/mild disease. Reducing vascular risk : many cases of dementia are mixed, including vascular contributions. GLP-1 agents help with cardiovascular risk, weight, hypertension, dyslipidemia—all of which affect brain blood vessels. Multiple mechanisms : the combination of improved glucose/insulin signaling + reduced inflammation + mitochondrial support + potential direct effects on amyloid/tau. This multipronged approach is promising, since dementia is multifactorial. Secondary benefits : weight loss, better diabetes management, improved overall metabolic health—benefits we already accept for GLP-1 agents even ignoring brain effects. Limitations & Unknowns While promising, there remain many uncertainties: Causality not yet proven : Many studies are associative. Randomized controlled trial (RCT) evidence is limited and not yet definitive for prevention. Duration of effect : Dementia develops over many years (often decades). Most trials and observational follow-ups so far are in the range of 1-5 years. We don’t yet know how long GLP-1 agents must be taken, or at what age, to achieve durable prevention. Selection of patients : It may be that benefits are strongest in those with early metabolic dysfunction, mild cognitive impairment, or early Alzheimer’s disease, rather than in advanced dementia. Timing likely matters. Drug choice, dose, and penetration : Differences among GLP-1 RAs in ability to affect the brain (blood–brain barrier penetration, receptor binding, half-life, dosing) may influence outcomes. Not all agents may perform equally in this regard. Side effects and risks : Though GLP-1 agents are generally well tolerated, they carry risk of gastrointestinal effects, possible rare pancreatitis, effects on gallbladder, etc. Also cost, access, monitoring. These must be weighed, especially in older patients or those with compromised renal or hepatic function. Non-diabetic populations : Most data so far are in people with T2DM or obesity. It's not yet established whether GLP-1 RAs will benefit people without those risk factors in preventing dementia. Clinical Implications & What I Might Recommend If you are interested in whether GLP-1 drugs might be protective for your brain, here’s how I’d think about integrating the current data into individualized care. Assess risk factors : Do you have type 2 diabetes? Prediabetes? Obesity? Hypertension? Dyslipidemia? Family history of AD? ApoE status (if tested)? These modify risk and may help decide how strongly to consider GLP-1 therapy for brain protection. Evaluate current indications : If you already qualify for a GLP-1 agent for diabetes, obesity, or cardiovascular risk, this brain effect adds more rationale. If you don’t, the risk vs benefit profile is different. Monitor cognition and brain health : If using GLP-1 agents, baseline cognitive testing (memory, executive function) and periodic follow-up may help document whether there is slowing of decline (though in routine practice, this is limited). Lifestyle remains foundational : Diet, exercise, sleep, managing cardiovascular risks remain essential. GLP-1 agents are not a substitute for those proven preventive measures. Research enrollment : If possible, enrolling in clinical trials designed to test GLP-1 RAs for dementia prevention or early AD may help (and give access to more intensive monitoring). Shared decision-making : If considering off‐label or “prevention” use, open discussion of uncertain benefit, possible side effects, cost, monitoring is essential. Where Research Is Heading / What to Watch For Larger RCTs in non-diabetic or prediabetic populations specifically targeting cognitive decline or dementia as endpoints. Head-to-head trials of different GLP-1 agents to see which have better brain penetration and efficacy. Studies of biomarkers (amyloid PET, tau imaging, MRI volumetrics) to detect early structural/functional changes. Long-term follow-ups (5-10+ years) to see if cognitive effects translate into reduced incidence of dementia, delayed institutionalization, preserved quality of life. Safety and tolerability in older age groups, polypharmacy, kidney, and hepatic impairment. So: Should You Use a GLP-1 Agent for Dementia Prevention? Here’s how I interpret the balance of evidence as of now. If you have type 2 diabetes or obesity and  are already considering a GLP-1 agent for metabolic reasons, then the potential brain benefits are a compelling additional advantage. If you do not  have metabolic disease, the idea of using GLP-1 purely for dementia prevention is more speculative. It might become standard in future, but I wouldn’t yet recommend it off-label purely for that purpose outside of research settings. Age, comorbidities, risk of side effects, cost, and your personal risk tolerance all matter. For someone with moderate risk, early metabolic dysfunction, family history, preserving cognition may tip the scale. Summary Alzheimer’s disease shows many features of insulin resistance in the brain, metabolic dysfunction, inflammation, oxidative stress: that’s the “type 3 diabetes” hypothesis. GLP-1 receptor agonists have multiple mechanisms that could  beneficially intervene in those pathological processes. Animal and mechanistic studies are strong; observational and early clinical trial data are promising. But we do not  yet have definitive proof in prevention — especially in long durations, in individuals without metabolic disease. If you are already using GLP-1 agents for metabolic disease, the potential cognitive benefits provide an added rationale. If not, it remains an area to watch and perhaps participate in trials. References Bae CS, et al. The Role of Glucagon-Like Peptide 1 (GLP-1) in Type 3 Diabetes: Glucose Metabolism, Amyloid, and Insulin Resistance in Alzheimer’s Disease . International Journal of Molecular Sciences.  2017;18(4):919. doi:10.3390/ijms18040919. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5713459/   PMC Atabi F, et al. A systematic review on type 3 diabetes: bridging the gap between diabetes and Alzheimer’s disease.   International Journal of Neuroscience.  2025. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12382249/   PMC Peng Y, et al. True or false? Alzheimer’s disease is type 3 diabetes.   Ageing Research Reviews.  2024; doi:10.1016/j.arr.2024.101051. Available from: https://www.sciencedirect.com/science/article/pii/S1568163724002010   ScienceDirect Du H, et al. The mechanism and efficacy of GLP-1 receptor agonists in Alzheimer’s disease.   Frontiers in Endocrinology.  2022;13:1033479. doi:10.3389/fendo.2022.1033479. Available from: https://www.frontiersin.org/articles/10.3389/fendo.2022.1033479/full?utm_source=chatgpt.com   Frontiers Hölscher C. GLP-1 class drugs show clear neuroprotective effects in first clinical trials in AD and PD patients.   Neuroscience & Biobehavioral Reviews.  2024. Available from: https://www.sciencedirect.com/science/article/pii/S0028390824001217   ScienceDirect Tang B, et al. Comparative effectiveness of glucagon-like peptide-1 receptor agonists and other second-line glucose-lowering agents for dementia outcomes in type 2 diabetes mellitus: A cohort study.   eClinicalMedicine.  2024;79:102635. doi:10.1016/j.eclinm.2024.102635. Available from: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00268-2/fulltext   The Lancet “GLP-1 Medications May Lower Dementia Risk, Research Suggests.” JAMA.  2025; (April). Anderer S, et al. Available from: https://jamanetwork.com/journals/jama/fullarticle/2833663   JAMA Network Wang W, et al. Associations of semaglutide with first-time diagnosis of dementia in people with type 2 diabetes.   Alzheimer’s & Dementia.  2024. Available from: https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14313   Alzheimer's & Dementia Journals Edison P, et al. Evaluating the Effects of the Novel GLP-1 Analogue Liraglutide in Alzheimer’s Disease (ELAD): Phase 2b randomized, double-blind, placebo-controlled trial.  Alzheimer’s Association International Conference (AAIC), 2024. Summary available from: https://aaic.alz.org/releases-2024/glp-drug-liraglutide-may-protect-against-dementia.asp   AAIC 2026 Li S, et al. GLP-1R as a potential link between diabetes and Alzheimer’s disease: Mechanistic insights and therapeutic opportunities.   Frontiers in Aging Neuroscience.  2025; Article 1601602. Available from: https://www.frontiersin.org/journals/aging_neuroscience/articles/10.3389/fnagi.2025.1601602/full   Frontiers Meng X, et al. Type 3 diabetes and metabolic reprogramming of brain neurons.   Molecular Medicine.  2025;31(1):101. doi:10.1186/s10020-025-01101-z. Available from: https://molmed.biomedcentral.com/articles/10.1186/s10020-025-01101-z   BioMed Central Monney M, et al. GLP-1 receptor agonists effect on cognitive function in diabetes: a systematic‐review / meta‐analysis.   Neuroscience & Biobehavioral Reviews.  2023; S1262-3636(23)00052-6. Available from: https://www.sciencedirect.com/science/article/pii/S1262363623000526   ScienceDirect “Weight Loss Drugs May Protect Against Alzheimer’s.” Alzinfo.org .  Reddin C, et al. 2025. Available from: https://www.alzinfo.org/articles/treatment/weight-loss-drugs-may-protect-against-alzheimers/   alzinfo.org “How GLP-1s Could Transform Alzheimer’s Treatment.” BrightFocus Foundation.  2025. Available from: https://www.brightfocus.org/resource/how-glp-1s-could-transform-alzheimers-treatment/   BrightFocus Foundation Kciuk M, et al. Alzheimer’s Disease as Type 3 Diabetes.   International Journal of Molecular Sciences.  2024;25(22):11955. doi:10.3390/ijms252211955. Available from: https://www.mdpi.com/1422-0067/25/22/11955/   MDPI Hölscher C. Protective effects of GLP-1 receptor agonists in neurodegeneration.  In: Neurotherapeutics. 2024. (“GLP-1 class drugs show clear protective effects…”). Available from: https://www.sciencedirect.com/science/article/pii/S0028390824001217   ScienceDirect Frontiers review: Du H, et al. (as above) discussing GLP-1 RAs’ mechanisms (ref. 4), especially insulin resistance in brain and oxidative stress. Frontiers Insulin resistance as molecular link between diabetes and AD. World Journal of Diabetes.  2024;15(7):1430-1445. Du C-T, et al. Available from: https://www.wjgnet.com/1948-9358/full/v15/i7/1430.htm   WJGNet The Danish registry study: Nerissa Nance, Andrew Mertens, et al. Applying the causal roadmap to longitudinal national registry data: a case study of second-line diabetes medication and dementia.  arXiv preprint. 2023. Available from: https://arxiv.org/abs/2310.03235   arXiv “GLP-1 receptor agonists effect on cognitive function in diabetes: a systematic review / meta-analysis.” (Monney et al., 2023) — repeated to emphasize the evidence in people with T2DM. Available from: https://www.sciencedirect.com/science/article/pii/S1262363623000526   ScienceDirect Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

Statins, GLP-1, and Metabolic Health: What Patients Should Know GLP-1 Medicines are beneficial in many ways If you take a statin to lower cholesterol, you’re in good company: statins are among the most widely prescribed medicines in the world. They reduce LDL (“bad cholesterol”) and convincingly lower the risk of heart attacks and strokes. That part is not in dispute. What is  being actively studied is how statins may influence blood-sugar control and a gut-derived hormone called GLP-1 (glucagon-like peptide-1), which helps regulate insulin release, appetite, and inflammation. Because GLP-1 also intersects with brain and blood-vessel health, patients often ask whether statins could nudge them toward diabetes or even affect cognition over time. Below is a plain-spoken tour of the best evidence we have today, plus practical steps you can take with your clinician to protect both your heart and your metabolism. GLP-1 in one minute GLP-1 is a hormone released by intestinal L-cells after you eat. Think of it as a “meal messenger” that: Helps the pancreas release insulin when glucose rises Tamps down glucagon (reduces liver glucose output) Slows stomach emptying so glucose rises more gently Sends satiety signals to the brain Boosting GLP-1 signaling—either by mimicking it (GLP-1 receptor agonists) or prolonging native GLP-1 (DPP-4 inhibitors)—improves glycemic control and reduces cardiometabolic risk in many patients. AHA Journals+1 A new twist: statins, the microbiome, bile acids… and lower GLP-1 GlP-1 influence many organs, including the liver, brain and stomach In 2024, a high-quality translational study reported that statins can aggravate insulin resistance by reducing circulating active GLP-1 levels —and that the effect appears to be microbiome-dependent . Mechanistically, statins altered the bile-acid pool (notably lowering ursodeoxycholic acid, UDCA), which reduced signaling through the TGR5 receptor on intestinal cells, leading to less GLP-1 release. In the human arm of the study, active GLP-1 concentrations fell significantly within four weeks  of atorvastatin therapy. Cell+1 Follow-up reviews summarize the idea this way: by shifting gut bacteria and bile acids, statins may unintentionally dial down your own GLP-1 signal—potentially nudging insulin resistance in the wrong direction, especially in those already at risk. Taylor & Francis Online That is not the last word (one paper never is), but it’s a credible biologic pathway linking statins → bile acids/microbiome → GLP-1 → insulin resistance. Do statins actually raise diabetes risk? Insulin resistance may be worsened by statin medications Short answer: yes, modestly —and the risk rises with higher-intensity dosing and in people already on the cusp of diabetes. An individual-participant meta-analysis of randomized trials (the most rigorous way to look) confirmed that statins increase the risk of new-onset diabetes , and clarified when and in whom it occurs. The Lancet+1 Mechanistic and clinical studies show increased insulin resistance  during statin therapy; for example, high-intensity atorvastatin over 10 weeks increased insulin resistance in non-diabetic adults. AHA Journals+1 Observational and trial meta-analyses consistently estimate a ~9–13% average increase  in diabetes risk across statins, with higher risks at intensive doses  (e.g., atorvastatin 80 mg), and particularly in those with pre-diabetes. nmcd-journal.com +1 A large cohort from Finland (METSIM) reported a higher, dose-responsive signal: 46% increased diabetes risk , tied to both decreased insulin sensitivity and insulin secretion. This is an outlier on the high end, but the design was careful and the pattern biologically plausible. PubMed+1 How might that tie back to GLP-1? The 2024 study suggests one pathway: if statins lower active GLP-1, the body’s post-meal insulin response and satiety signaling could be blunted, tending toward higher glucose and weight—especially in those with pre-existing insulin resistance. Cell What if I already have pre-diabetes? Pre-diabetes is a tipping-point condition. In several analyses, statin-associated dysglycemia is most evident in people who started close to that metabolic edge . High-intensity statins show the largest signal, and the effect appears dose-dependent. That’s not a reason to ignore your LDL or stop therapy abruptly; it is  a reason to individualize choices, intensify lifestyle therapy, and monitor glucose and A1c more closely. ScienceDirect+1 In short, know the risk-benefit analysis. Statins need not be given to everybody. Often, it seems, they are prescribed to everybody, as we have so frequently been told, 'The lower the cholesterol, the better.' From an observational standpoint, as well as a personal experiential standpoint, is entirely wrong. What about memory and dementia? Here the evidence is mixed  and, importantly, not  aligned with a clear harm signal: The FDA added labeling in 2012 noting rare, generally reversible  reports of memory loss or confusion with statins; they also noted small increases in blood sugar. This is real-world pharmacovigilance—signals to watch, not proof of ongoing injury. U.S. Food and Drug Administration+1 Randomized evidence to date has not shown prevention of dementia  by starting statins late in life; a Cochrane review concluded there was “good evidence” that statins do not  prevent cognitive decline or dementia in that context. Cochrane Library+1 Large observational syntheses are heterogeneous: some show neutral  effects; others suggest protective associations  (lower dementia risk among statin users). Observational results can be confounded (healthier users, better vascular care, etc.), so they don’t settle causality. Oxford Academic+1 Diabetes and Statins may contribute to Alzheimer's disease How do we square this with GLP-1? Chronically higher glucose and insulin resistance are linked to worse brain outcomes over time. If statins in some people  nudge glucose up (possibly via lower GLP-1), that metabolic effect could, indirectly, be unfavorable for the brain. But head-to-head evidence that statins cause  dementia is lacking, and several analyses point the other way. The most sensible stance: treat the vascular risk we know statins improve, while actively protecting metabolic and cognitive health with monitoring and targeted add-ons when needed.   The Lancet+1 Practical counseling: how we minimize downside while keeping upside Stratify your baseline risk. If your 10-year ASCVD risk is high, the cardiovascular benefits of statins are substantial. If your risk is moderate and you also have pre-diabetes, we weigh options more carefully (dose, molecule, or alternatives such as ezetimibe or bempedoic acid). Evidence of a small diabetes signal should be framed against the larger  heart-attack/stroke risk reduction in higher-risk patients. The Lancet Choose dose and molecule deliberately. Higher-intensity regimens carry a larger glycemic signal. Discuss whether a moderate-intensity statin  plus ezetimibe  (or bempedoic acid ) can reach LDL goals with less metabolic friction. nmcd-journal.com Track glucose proactively. Check fasting glucose, A1c, and—in those on the cusp—consider occasional post-meal  checks or a short CGM  trial to see what meals and medicines do in real life. Adjust diet (fiber, protein in early meals), activity (walks after meals), and timing. ScienceDirect Reinforce GLP-1–friendly habits. Protein with breakfast, viscous fibers (oats, legumes), fermented foods, and resistance training can all improve incretin tone and insulin sensitivity. If weight, appetite, or post-meal spikes worsen after starting a statin, bring this up—don’t white-knuckle it. Pharmacologic add-ons if needed. In people who develop hyperglycemia on statins—or who begin with pre-diabetes—consider therapies that enhance GLP-1 signaling  (GLP-1 receptor agonists, DPP-4 inhibitors) or improve insulin sensitivity (metformin) while continuing evidence-based lipid lowering. Drug–drug interactions with GLP-1 RAs are generally minor (slower gastric emptying can lower peak levels of some oral drugs), and the benefits for cardiometabolic risk are well established. SpringerLink+1 Cognition: monitor, don’t panic. If you notice new brain-fog or short-term memory issues after a statin starts or a dose increases, tell your clinician. Many cases are reversible  with dose adjustment or a switch in agent. Meanwhile, control of blood pressure, sleep apnea, glucose, exercise, and social/cognitive engagement are the heavy hitters for brain protection. U.S. Food and Drug Administration Bottom line for patients Statins may save lives,  by preventing heart attacks and strokes. A growing body of evidence indicates they can nudge glucose upward  and increase diabetes risk , particularly at higher doses and in those with pre-diabetes. A mechanistic link —reduced active  GLP-1 via microbiome/bile-acid changes—has now been demonstrated in humans. This, on the other hand, may cost lives. Cell Cognitive effects remain uncommon and typically reversible  when they occur; large randomized data do not  show dementia prevention from initiating statins late in life, and observational data on dementia risk are mixed . Cochrane Library+1 The best approach isn’t “statins good” or “statins bad.” It’s statins plus metabolic vigilance : choose the right intensity, monitor glucose, support GLP-1 biology with lifestyle (and, when appropriate, medication), and keep the heart-brain-metabolism picture in view. There is a time and a place for statin medications, but using them without better consideration of the populations at risk, will result in increased incidence of diabetes, obesity and dementia. Focus diagnosis and therapeutics on the inflammatory markers, as atherosclerosis starts as intravascular inflammation. Reduce inflammation through a better understanding of the factors that lead to intravascular inflammation, and intervene according to the chemistry that is required. Reduce the cholesterol value using natural and/or dietary approaches first. Statins have a bad public reputation, for no other reason than they make a significant number of persons 'feel bad,' as they are taken. References (15) She J , et al. Statins aggravate insulin resistance through reduced blood glucagon-like peptide-1 levels in a microbiota-dependent manner.   Cell Metab.  2024;36(2):408-421.e5. doi:10.1016/j.cmet.2023.12.027. [PubMed/Abstract] PubMed She J , et al. A gut feeling of statin: How gut microbiota modulate the therapeutic and side effects of statins.   Gut Microbes.  2024;16(1):e2291678. [Article] Taylor & Francis Online Cholesterol Treatment Trialists’ Collaboration  (Reith C, et al.). Effects of statin therapy on diagnoses of new-onset diabetes: individual participant data meta-analysis.   Lancet Diabetes Endocrinol.  2024;12(6):xxx-xxx. [Article/Abstract] The Lancet+1 Abbasi F , et al. Statins are associated with increased insulin resistance and insulin secretion in adults without diabetes.   Arterioscler Thromb Vasc Biol.  2021;41(11):e443-e455. [Article] AHA Journals Laakso M.   Statins and risk of type 2 diabetes: mechanism and clinical implications.   Front Endocrinol.  2023;14:1239335. [PMC] PMC Alvarez-Jimenez L , et al. Effects of statin therapy on glycemic control and insulin resistance: meta-analysis.   Pharmacol Res.  2023;190:106695. [Abstract] ScienceDirect Cederberg H , et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: METSIM cohort.   Diabetologia.  2015;58:1109-1117. [PubMed] PubMed Crandall JP , et al. Statin use and risk of developing diabetes: Women’s Health Initiative.   J Gen Intern Med.  2017;32(7):746-753. [PMC] PMC Casula M , et al. Statin use and risk of new-onset diabetes: meta-analysis of observational studies.   Nutr Metab Cardiovasc Dis.  2017;27(5):396-406. [Article] nmcd-journal.com Navarese EP , et al. Impact of different statin types/doses on new-onset diabetes: meta-analysis.   Am J Cardiol.  2013;111(8):1123-1130. [Abstract] ajconline.org Barkas F , et al. High-intensity statin therapy and incident diabetes—greater risk in prediabetes.   J Clin Lipidol.  2016;10(4):e-pub ahead of print. [Abstract] ScienceDirect Dabhi KN , et al. Assessing the link between statins and insulin intolerance: systematic review.   Cureus.  2023;15(6):e40112. [PMC] PMC U.S. FDA.   Drug Safety Communication: Safety label changes for statins (cognition and blood glucose).  2012. [FDA page] U.S. Food and Drug Administration McGuinness B , et al. Statins for the prevention of dementia.   Cochrane Database Syst Rev.  2016;CD003160. [Abstract] Cochrane Library Olmastroni E , et al. Statin use and risk of dementia or Alzheimer’s disease: meta-analysis of observational studies.   Eur J Prev Cardiol.  2022;29(5):804-814. [Article] Oxford Academic A final word If you’re on a statin (or considering one) and you also have pre-diabetes, diabetes, weight gain, or cognitive concerns, the right move is not  to stop therapy on your own. It’s to personalize  the plan: the right LDL goal, the right intensity, early glucose monitoring, GLP-1–supportive lifestyle (and medications if needed), and open communication about symptoms. That balanced strategy preserves the heart-protection statins offer while addressing the metabolic side of the ledger with equal seriousness. Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

The Warburg effect, decoded Whatis the Warburg Effect? Nearly a century ago, Otto Warburg observed that many tumors avidly ferment glucose to lactate even when oxygen is plentiful—so-called aerobic glycolysis . Rather than fully oxidizing glucose in mitochondria to squeeze out maximal ATP, cancer cells divert a large fraction of glucose carbon toward rapid ATP generation and biosynthesis  (nucleotides, amino acids, lipids) needed for proliferation. Warburg originally argued this reflected “injured respiration”; modern work shows the reality is more nuanced: oncogenic signaling and the tumor microenvironment reprogram  metabolism to favor glycolysis while mitochondria remain functional and essential for anabolism and redox balance. Understanding this principal is key to cancer prevention . refp.cohlife.org PMC Science In contemporary cancer biology, metabolic reprogramming is recognized as a hallmark of malignancy. This reprogramming is not simply about energy; it’s a control system  that tunes redox state, epigenetic marks, and immune evasion. As Hanahan’s updated “Hallmarks of Cancer: New Dimensions” emphasizes, altered metabolism is intertwined with genomic instability, inflammation, and immune escape—features that collectively enable tumor progression. PubMed Why glycolysis becomes an advantage How understanding the Warburg Effect may improvie your longevity Glycolysis is fast. When coupled to high glucose uptake and lactate export (via monocarboxylate transporters), it enables cells to grow under fluctuating oxygen  and to sustain the pentose phosphate pathway and one-carbon metabolism. The acidified microenvironment created by lactate (pH ~6.3–6.9) promotes invasion, angiogenesis, and immune suppression. Lactate is not merely “waste”; it’s a signaling metabolite  that shapes gene expression (including histone lactylation ) and alters the behavior of stromal and immune cells. Clinically, our exploitation of this phenotype underpins FDG-PET , which images tumors because they often take up far more 18F-fluorodeoxyglucose than surrounding tissues. PMC+1 Nature Prevention: what the Warburg effect teaches us It is crucial to avoid over-claiming: no diet or supplement “shuts off” the Warburg effect  across cancers. That said, the phenotype highlights upstream levers— adiposity, insulin/IGF-1 signaling, and physical inactivity —that create a metabolic milieu favorable to glycolysis-dependent growth. Observational and mechanistic data connect chronic hyperinsulinemia and insulin resistance  to higher risks of several cancers; insulin acts as a growth factor and can increase glucose uptake and glycolytic flux in susceptible tissues. PMC+1 Body weight and body composition.  Excess adiposity fosters hyperinsulinemia, chronic inflammation, and altered adipokines—all of which tilt cells toward glycolytic programs and anabolic growth. Global consensus statements from the World Cancer Research Fund/AICR estimate that maintaining a healthy weight and limiting weight gain across adulthood lowers risk for multiple cancers. World Cancer Research Fund Physical activity.  Regular activity improves insulin sensitivity, reduces chronic inflammation, and enhances mitochondrial oxidative capacity—physiologic counterweights to the Warburg phenotype. Evidence syntheses and guidelines recommend 150–300 minutes/week of moderate  or 75–150 minutes/week of vigorous  activity, with more generally better; adherence is associated with lower incidence and mortality across several cancers. American Cancer Society PMC+1 Dietary pattern and carbohydrate quality.  The Warburg frame sometimes inspires extreme carbohydrate restriction; evidence for universal cancer-prevention benefit of very low-carb or ketogenic diets remains limited. More solid is the signal that dietary patterns  emphasizing fiber-rich, minimally processed foods (vegetables, fruits, legumes, whole grains) and minimizing refined starches and added sugars  improve metabolic health and may lower risk of several cancers, notably colorectal. Meta-analytic and cohort data link higher glycemic load  or poor carbohydrate quality to elevated colorectal cancer risk in some populations. PMC+1 ScienceDirect How clinicians already leverage the phenotype The Warburg effect is not just a laboratory curiosity; it has diagnostic  and therapeutic  implications. FDG-PET/CT uses tumor glycolysis to localize disease and monitor response; in parallel, a wave of investigational strategies attempts to target metabolic nodes  (glycolysis, lactate transport, redox recycling) or to recondition  the microenvironment. While these approaches are still maturing clinically, they reflect a central point: tumor metabolism is plastic  and intertwined with signaling, epigenetics, and immunity. Journal of Nuclear Medicine Nature Practical, evidence-anchored takeaways Manage insulin exposure.  Maintain a healthy waist circumference; prioritize dietary patterns that blunt post-prandial spikes (fiber-rich, minimally processed foods) and distribute carbohydrates with protein and healthy fats. For people with diabetes or prediabetes, evidence-based management (diet, exercise, medications as indicated) matters for cancer prevention as well as cardiometabolic health. PMC Move more, most days.  Accumulate at least the ACS-recommended activity minutes weekly, and reduce sedentary time. Even small increments improve insulin sensitivity and mitochondrial function, pushing cellular metabolism away from glycolysis-dominant states. American Cancer Society Think in patterns, not magic bullets.  No single food or supplement reliably “starves” cancer. Focus on patterns—weight control, fitness, high-quality carbohydrate, limited alcohol, and smoking cessation—that harmonize metabolism and reduce inflammatory tone long-term. World Cancer Research Fund Bottom line The Warburg effect captures a fundamental reprogramming that makes growth possible under stress; it also offers a lens for prevention. By improving insulin sensitivity , reducing chronic inflammation , and reinforcing mitochondrial health  through diet and physical activity, we make it harder for premalignant cells to inhabit a glycolysis-favored niche. That’s not a guarantee—but it is a principled, evidence-based way to shift risk in our favor. References (publication format with links) Warburg O. On the Origin of Cancer Cells.   Science.  1956;123(3191):309–314. https://www.science.org/doi/10.1126/science.123.3191.309   Science DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism.   Sci Adv.  2016;2(5):e1600200. https://www.science.org/doi/10.1126/sciadv.1600200   Science DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism.   Sci Adv.  2016;2(5):e1600200. (Open-access version) https://pmc.ncbi.nlm.nih.gov/articles/PMC4928883/   PMC Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation.   Cell.  2011;144(5):646–674. https://pubmed.ncbi.nlm.nih.gov/21376230/   PubMed Hanahan D. Hallmarks of Cancer: New Dimensions.   Cancer Discov.  2022;12(1):31–46. https://pubmed.ncbi.nlm.nih.gov/35022204/   PubMed Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression.   Science.  2020;368(6487):eaaw5473. https://www.science.org/doi/10.1126/science.aaw5473   Science Ippolito L, et al. Lactate: A Metabolic Driver in the Tumour Landscape.   Trends Cell Biol.  2019;29(10):748–762. https://www.sciencedirect.com/science/article/abs/pii/S0968000418302275   ScienceDirect Pérez-Tomás R, Pérez-Guillén I. Lactate in the Tumor Microenvironment: An Essential Molecule in Cancer Progression and Treatment Resistance.   Cancers (Basel).  2020;12(11):3244. https://pmc.ncbi.nlm.nih.gov/articles/PMC7693872/   PMC Chen J, et al. Lactate and lactylation in cancer.   Signal Transduct Target Ther.  2025;10:??? (online). https://www.nature.com/articles/s41392-024-02082-x   Nature Kawada K, et al. Mechanisms underlying 18F-fluorodeoxyglucose accumulation in colorectal cancer.   Int J Clin Oncol.  2016;21(5):898–906. https://pmc.ncbi.nlm.nih.gov/articles/PMC5120247/   PMC Salas JR, et al. Signaling Pathways That Drive 18F-FDG Accumulation in Cancer.   J Nucl Med.  2022;63(5):659–666. https://jnm.snmjournals.org/content/63/5/659   Journal of Nuclear Medicine Perry RJ, et al. Mechanistic Links between Obesity, Insulin, and Cancer.   Trends Endocrinol Metab.  2020;31(10):684–695. https://pmc.ncbi.nlm.nih.gov/articles/PMC7214048/   PMC Jee SH, et al. Obesity, Insulin Resistance and Cancer Risk.   Yonsei Med J.  2005;46(3):449–455. https://pmc.ncbi.nlm.nih.gov/articles/PMC2815827/   PMC American Cancer Society. Guideline for Diet and Physical Activity for Cancer Prevention.  Updated May 5, 2025. https://www.cancer.org/cancer/risk-prevention/diet-physical-activity/acs-guidelines-nutrition-physical-activity-cancer-prevention/guidelines.html   American Cancer Society World Cancer Research Fund/AICR. Diet, Nutrition, Physical Activity and Cancer: A Global Perspective (Third Expert Report).  2018. https://www.wcrf.org/wp-content/uploads/2024/11/Summary-of-Third-Expert-Report-2018.pdf   World Cancer Research Fund Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

Nutraceutical Approaches to Lowering Insulin and Supporting Diabetes Management & Weight Elevated Insulin Puts You at High Risk for Diabetes Berberine: An AMPK Activator with Insulin-Lowering Effects Berberine, an isoquinoline alkaloid extracted from plants like Berberis vulgaris , is one of the most extensively studied natural compounds for metabolic health. Its primary mechanism involves the activation of AMP-activated protein kinase (AMPK) , often described as a “metabolic master switch.” By activating AMPK, berberine enhances glucose uptake in skeletal muscle, reduces hepatic glucose production, and improves overall insulin sensitivity. Clinical trials demonstrate that berberine can lower fasting glucose, HbA1c, and fasting insulin to an extent comparable with first-line pharmaceuticals such as metformin. Additional benefits include improvement in lipid profiles and favorable modulation of gut microbiota, both of which reduce the systemic inflammation that contributes to insulin resistance. Berberine lowers insulin and blood sugar simultaneously. Berberine 500 mg take 1 capsule twice to four times, daily Chromium Picolinate and Vanadyl Sulfate: Trace Elements Influencing Insulin Action Chromium, especially in the form of chromium picolinate, functions as a cofactor that enhances insulin receptor activity and improves intracellular signaling. Supplementation has been shown in human trials to improve glucose tolerance, lower fasting glucose, and reduce insulin resistance — though effects tend to be most pronounced in individuals with suboptimal chromium status. Vanadyl sulfate, a form of the trace mineral vanadium, mimics insulin at the receptor level and activates downstream pathways to promote glucose uptake while suppressing hepatic glucose output. Clinical studies show that vanadyl sulfate can lower blood glucose and improve insulin sensitivity in type 2 diabetes, but its long-term use is limited by safety concerns related to gastrointestinal tolerance and potential toxicity. Both agents highlight how micronutrients can intersect with cellular insulin signaling, but they should be used with medical oversight. Diabet Stat II Take 1 capsule twice daily Inositol: Restoring Second Messenger Function in Insulin Signaling Inositol, particularly myo-inositol  and D-chiro-inositol , serves as a critical second messenger in insulin signaling. When this pathway falters, tissues become less responsive to insulin, perpetuating hyperinsulinemia. Supplementation with inositol has been shown to restore proper signaling, improving insulin sensitivity and lowering both glucose and fasting insulin levels. Clinical studies in women with polycystic ovary syndrome (a condition tightly linked to insulin resistance) show improved ovulation, reduced androgen excess, and better metabolic profiles. In the broader population with metabolic syndrome or diabetes, inositol supplementation has demonstrated modest improvements in HOMA-IR, triglycerides, and HbA1c, supporting its role as a low-risk adjunct to diet and exercise. Inositol 500 mg capsules Take 2 twice daily Olive Leaf Extract: Harnessing Polyphenols for Metabolic Health Olive leaf extract, derived from Olea europaea , contains powerful polyphenols such as oleuropein and hydroxytyrosol, compounds also abundant in extra-virgin olive oil. These molecules exert antioxidant and anti-inflammatory effects but also act directly on glucose metabolism. Mechanistically, olive leaf polyphenols enhance glucose uptake in peripheral tissues, increase GLUT4 translocation, and reduce oxidative stress that impairs insulin signaling. Human trials have shown that olive leaf supplementation can lower fasting glucose and HbA1c while improving lipid profiles and reducing inflammatory markers. Because of its cardiovascular benefits and general safety, olive leaf extract is emerging as a promising complementary intervention for those at risk of or living with type 2 diabetes. References Berberine Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus.   Metabolism.  2008;57(5):712-717. PubMed Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine.   J Clin Endocrinol Metab.  2008;93(7):2559-2565. PubMed Dong H, Wang N, Zhao L, Lu F. Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis.   Evid Based Complement Alternat Med.  2012;2012:591654. PubMed Deng Y, Zhang Q, Li Y, et al. Berberine attenuates insulin resistance by enhancing insulin signaling and AMPK pathway in high-fat diet induced obese mice.   Nutrients.  2020;12(9):2688. PubMed Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.   J Ethnopharmacol.  2015;161:69-81. PubMed Chromium Polynicotinate & Vanadyl Sulfate Anderson RA, Bryden NA, Polansky MM, et al. Chromium supplementation of human subjects: effects on glucose, insulin, and lipids.   Metabolism.  1997;46(8):1-10. PubMed Balk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG. Effect of chromium supplementation on glucose metabolism and lipids: systematic review of RCTs.   Diabetes Care.  2007;30(8):2154-2163. PubMed Martin J, Vincent JB. Mineral-dependent insulin-mimetic compounds: vanadium, chromium, zinc, and selenium.   J Trace Elem Med Biol.  2007;21(1):59-65. PubMed Bal A, Singh AK. Effect of vanadium and its compounds on carbohydrate metabolism.   Endocr Pract.  2008;14(7):886-889. PubMed Waring MJ, Sanders JA. Tolerance of diabetics to oral vanadyl sulfate.   Diabetes Res Clin Pract.  1995;28(1):57-60. PubMed Inositol & Olive Leaf Extract Pintaudi B, Di Vieste G, Bonomo M. Myo-inositol may improve insulin resistance and metabolic syndrome in type 2 diabetes patients.   Int J Endocrinol.  2016;2016:9132054. PubMed Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in PCOS with D-chiro-inositol.   N Engl J Med.  1999;340(17):1314-1320. PubMed Konstantinidou V, et al. In vivo nutrigenomic effects of virgin olive oil polyphenols within the frame of the Mediterranean diet: modulation of inflammation and oxidative stress in humans.   BMC Genomics.  2010;11:253. PubMed Wainstein J, Ganz T, Boaz M, et al. Olive leaf extract improves insulin sensitivity in humans.   J Med Food.  2012;15(7):605-610. PubMed Lockyer S, Rowland I, Spencer JP, et al. Impact of phenolic-rich olive leaf extract on blood pressure, plasma lipids and inflammatory markers: randomized controlled trial.   Eur J Nutr.  2017;56(4):1421-1432. PubMed Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

Migraines and Sinus Headaches can strike any time, anywhere and be a painful disruption to your day. Understanding migraine vs. sinus headache matters because the right diagnosis drives the right treatment. Below is a clear, patient-friendly  guide to tell them apart and get you closer to effective relief. What Are Migraines?  A migraine  is a neurological disorder marked by moderate to severe throbbing or pulsating head pain, often on one side, commonly accompanied by nausea and sensitivity to light and sound. Some people experience a visual or sensory "aura" before or during the attack.  Common Symptoms of Migraine vs Sinus Headache, Also Called a Sinus Migraine Typical migraine signs include throbbing pain (often unilateral), nausea and/or vomiting, photophobia (light sensitivity), and phonophobia (sound sensitivity). Nasal symptoms like a runny or stuffy nose and tearing can occur with migraine and are a major reason it's mistaken for a sinus problem.  Both sinus headaches and migraines can cause runny noses and watery eyes, making diagnosis by a qualified clinicians even more crucial to treatment. Causes and Triggers: Where "Sinus Migraine" Confusion Starts Common migraine triggers include stress, dehydration, sleep changes, skipped meals, certain foods, and hormonal fluctuations. These triggers can overlap  with allergy season or a lingering cold when nasal symptoms are also common.  Who Is at Risk? Migraines can affect anyone, but women are about three times more likely than men to experience them. Family history and certain co-existing conditions  (like anxiety, depression, and sleep disorders) also raise risk.  What Are Sinus Headaches? True sinus headaches  happen when the lining of the sinus cavities is inflamed (sinusitis), creating pressure and pain in the face and forehead. Because both conditions can involve facial pain and nasal symptoms, sinus headache vs migraine can be tricky to untangle without a careful exam.  Common Symptoms of Sinus Headache vs Migraine Sinusitis typically causes facial pressure or fullness (cheeks, forehead, between/behind the eyes), nasal congestion and discharge, postnasal drip, tooth pain, possible fever, and pain that worsens when you bend forward. These features are different from migraine's hallmark nausea and sensory sensitivities.  Underlying Causes (Allergy, Infection, Structure) Sinus inflammation can stem from viral infections, bacterial infections, allergies, or structural issues like a deviated septum or polyps. Managing allergies and nasal inflammation is often key to reducing sinus-related headaches.  How Sinus Headaches Are Diagnosed A clinician can often diagnose sinusitis  by history and exam; in some cases, nasal endoscopy or CT imaging is used - particularly for chronic or recurrent cases or when complications are suspected. Routine imaging is not recommended for uncomplicated acute sinusitis.  Key Differences Between Migraine vs Sinus Headache Pain Location and Type Migraine:  Pulsing/throbbing pain, often on one side; may spread; worsens with activity. Sinus headache:  Pressure-like, deep, constant pain over the cheeks, forehead, or bridge of the nose, often with tenderness. Accompanying Symptoms (Nausea, Congestion, Sensitivity) Migraine:  Nausea/vomiting; light and sound sensitivity; may include aura; nasal tearing/runny nose can occur. Sinus headache : Thick nasal discharge, congestion, postnasal drip, possible fever, reduced smell. Duration and Frequency Migraine:  Individual attacks often last 4-72 hours. Sinusitis-related headache:  Often persists for a week to 10 days or longer, tracking the course of the infection/inflammation. About 90% of self-diagnosed sinus headaches are actually migraines. Only a qualified doctor can make the property diagnosis. Why Misdiagnosis Is Common Migraines can trigger autonomic nasal symptoms (runny/stuffy nose, watery eyes), so it can feel like a "sinus migraine." Because both conditions can follow a cold or seasonal allergies, people (and even clinicians without a full history) may lean toward sinusitis. The American Migraine Foundation notes that about 90% of self-diagnosed sinus headaches are actually migraines.  How to Get an Accurate Diagnosis Importance of Medical Evaluation If you frequently get "sinus" pain plus nausea or light/sound sensitivity - or if over-the-counter decongestants never seem to help-ask your clinician to consider migraine vs sinus headache. A targeted history (triggers, family history, aura, disability level) and focused exam are usually enough to distinguish the two.  Role of Imaging and Testing For uncomplicated acute sinusitis, routine imaging isn't recommended; clinicians reserve CT or endoscopy for recurrent/chronic cases, atypical features, or suspected complications. Conversely, most people with stable, typical migraine don't need brain imaging. Treatment Options: Sinus Headache vs Migraine Treatments for Migraines Acute relief: NSAIDs or acetaminophen at onset; prescription triptans; some may use gepants (CGRP receptor antagonists) or ditans under clinician guidance. Ditans and gepants are n ew migraine treatments  that differ slightly from existing therapies. These new medications provide additional options for people with migraine for whom other medications may be at risk of side effects. Preventive options:  CGRP monoclonal antibodies, beta-blockers, topiramate, certain antidepressants, and onabotulinumtoxinA (Botox) for chronic migraine. Lifestyle support :  Sleep regularity, hydration, stress management, trigger tracking. Treatments for Sinus Headaches Self-care & s ymptom relief : Nasal saline irrigation, intranasal corticosteroid sprays, humidification, and cautious short-term use of decongestant sprays (avoid more than 3-5 days). When antibiotics help:  Many acute sinus infections are viral and resolve on their own; clinicians may consider antibiotics for uncomplicated acute bacterial sinusitis after watchful waiting or when specific criteria are met. Chronic or recurrent cases: Evaluate for allergies or structural contributors; ENT referral and, rarely, surgery may be considered. When to See a Specialist (Headache or Sinus Care) Your "sinus headaches" come with nausea/vomiting or light/sound sensitivity. Headaches last 4-72 hours and keep returning despite "sinus" treatments.  You have chronic congestion, facial pain, or infections that persist beyond 10-14 days or keep recurring.  Any red flags (sudden "worst headache," new neurological symptoms, stiff neck, high fever, vision changes) require urgent care. If you're tired of guessing between sinus headache vs migraine, our team can help you pin down the cause and build a plan that works-whether that means modern migraine care, targeted sinus treatment, or both. Schedule a thorough evaluation  at the Stages of Life Medical Institute. David S. Klein, MD, FACA, FACPM For information in becoming a patient, follow this link.

Occipital Neuralgia results from a nerve entrapment at the upper part of the neck. At Stages of Life Medical Institute , we meet patients every week who come to us with a puzzling and debilitating pain that starts at the base of the skull and radiates upward into the scalp or even behind the eye. This condition, called occipital neuralgia , is often mistaken for migraine or tension headache—but it has its own causes, diagnostic criteria, and effective treatments. Often confused with migraine, Greater Occipital Neuralgia is caused by mechanical irritation, compression or damage to the delicate nerves that run from the base of the skull through the posterior, supportive muscles of the neck. The confusion with migraine begins with the overlap of symptoms between the two conditions, including intense pain, nausea, and eye pain. Our goal is to first diagnose your condition with precision , and offer targeted therapies that restore quality of life while avoiding unnecessary interventions. The occipital nerves run below the scalp and are easily damaged by being pinched by the muscles of the neck and may be crushed against the bone of the skull. What is Occipital Neuralgia? Occipital neuralgia is a common medical condition that arises when the greater, lesser, or third occipital nerves —which carry sensation from the upper neck and back of the head—become compressed or irritated. Patients often describe: Sharp, stabbing, “electric” jabs of pain  lasting seconds to minutes. A dull, lingering ache  between flares. Tenderness  along the nerve’s path, often just below the skull. Sensitivity to touch —even a pillow or a hat can trigger pain. Why Does Occipital Neuralgia Happen? The occipital nerves can be pinched as they weave through muscles and connective tissue in the neck. Common culprits include: Postural strain (long hours at a computer, poor ergonomics). Whiplash injuries, extension or rotational injuries of the head and neck. Arthritis of the upper cervical spine (C2–C3). Postsurgical scarring or muscular tightness. Blunt trauma We must differentiate greater occipital neuralgia from trigeminal neuralgia and other causes of occipital headache How We Diagnose at Stages of Life Our evaluation begins with a detailed history and hands-on examination . We look for hallmark signs such as nerve tenderness and pain triggered by light touch. When the story and exam point toward occipital neuralgia, we first place the patient on anti-inflammatory medications, selected muscle relaxants and membrane stabilizing medications. We select from a variety of prescription and non-prescripotion choices, depending entirely on the clinical situation. More times than not, this provides substantial relief. If necessary, we may decide to perform a diagnostic nerve block —injecting a small amount of numbing medicine around the nerve. Immediate relief confirms the diagnosis. Sometimes we repeat the block to eliminate false positives. We also rule out mimics like migraine or cervicogenic headache, using imaging or further testing, only if there are red flags. Treatment Options for Greater Occipital Neuralgia: Stepwise and Targeted At Stages of Life, our philosophy is to start simple, then step up only as needed : Lifestyle & Conservative Measures: Posture correction, ergonomic coaching, gentle neck rehabilitation, and sleep optimization. Medications: Neuropathic agents (gabapentin, tricyclics) and nonsteroidal anti-inflammatories can help some patients. Occipital Nerve Blocks: Both diagnostic and therapeutic, these injections often provide immediate relief. With ultrasound guidance, we maximize precision and safety. Our Patient Journey When you walk into Stages of Life Medical Institute , you can expect: A thorough evaluation by a board-certified physician. Clear explanations and reassurance. Tailored treatment—starting with conservative steps and progressing to advanced interventions only when necessary. Our services are performed in the office setting, minimizing collateral costs to the patient, we are located conveniently in our own office building with substantial available parking, close by. Our integrative approach means that whether you need lifestyle coaching, targeted injections, or state-of-the-art neuromodulation, your care is anchored in compassion, precision, and science. References: Headache Classification Committee of the International Headache Society. “ 13.4 Occipital neuralgia .” ICHD-3 (2018).   ichd-3.org   ICHD-3 Djavaherian DM, et al. “ Occipital Neuralgia .” StatPearls  (updated 2023). NCBI Bookshelf   NCBI Austin M, et al. “ Occipital Nerve Block .” StatPearls  (updated 2023). NCBI Bookshelf   NCBI Shim JH, et al. “ Ultrasound-guided greater occipital nerve block .” Korean J Anesthesiol  2011. PMC   PMC Barmherzig R, Kingston W. “ Occipital Neuralgia and Cervicogenic Headache: Diagnosis and Management .” Curr Neurol Neurosci Rep  2019. PDF   painschoolinternational.com Scherer SS, et al. “ The Greater Occipital Nerve and Obliquus Capitis Inferior .” Plast Reconstr Surg  2019. Journal site  Lippincott Journals Sağlam L, et al. “ Morphological features of the greater occipital nerve and its muscular relations .” Surg Radiol Anat  2023. PMC   PMC Kim HS, et al. “ Stereotactic topography of the greater and third occipital nerves .” Sci Rep  2018. Nature   Nature Juškys R, et al. “ Effectiveness of treatment of occipital neuralgia using occipital nerve block .” Medicina (Kaunas)  2018. PMC   PMC Batistaki C, et al. “ Pulsed Radiofrequency of the Occipital Nerves .” Pain Res Manag  2021. PMC   PMC De Oliveira K, et al. “ Pulsed Radiofrequency Neuromodulation of the Greater Occipital Nerve: Systematic Review .” Can J Pain  2024. Taylor & Francis   Taylor & Francis Online Manolitsis N, Elahi F. “ Pulsed Radiofrequency for Occipital Neuralgia: Review .” Pain Physician  2014. PDF   Pain Physician Journal Montenegro MM, et al. “ Long-term outcomes of occipital nerve stimulation .” Headache  2023. PMC   PMC Lam KHS, et al. “ Ultrasound-guided hydrodissection with 5% dextrose for occipital neuralgia .” Diagnostics  2024. MDPI   MDPI Ruberto N, et al. “ Percutaneous peripheral nerve stimulation for occipital neuralgia (case report) .” Orthopedic Reviews  2025. Open Medical Publishing   Orthopedic Reviews Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

Alzheimer's disease affects millions worldwide, leading to profound cognitive decline and memory loss. As researchers seek effective treatments, lithium—traditionally prescribed for bipolar disorder—has gained attention as a potential ally in the battle against Alzheimer's. This blog post will explore the latest insights into the benefits of lithium and its role in Alzheimer's treatment, outline future directions for research in this critical area. Low dose lithium has demonstrating remarkable promise in the prevention and treatment of Alzheimer's disease and Memory Loss. Complex Problems frequently have Complex Solutions Understanding the Benefits of Lithium's Mechanism of Action in Preventing Alzheimer's Dementia Lithium is commonly recognized for its mood-stabilizing effects, but it also exhibits neuroprotective properties relevant to Alzheimer's disease. Research indicates that lithium may inhibit the formation of amyloid-beta plaques and tau tangles, which are key contributors to Alzheimer's pathology. Specifically, lithium's ability to inhibit glycogen synthase kinase 3 (GSK-3) can promote neuron survival and bolster neurogenesis. This action not only helps to preserve cognitive function but also suggests a promising therapeutic path for Alzheimer's patients. Why would lithium affect Alzheimer’s at all? Lithium influences several cellular pathways tied to Alzheimer’s biology. In lab and early clinical studies, lithium appears to dampen an enzyme called GSK-3β   (which helps add phosphate groups to tau), support autophagy  (the brain’s “cleanup” system for misfolded proteins such as amyloid-β), and promote nerve-growth signals like BDNF  that support synapses. These mechanisms map onto the two hallmark pathologies of Alzheimer’s—amyloid plaques and tau tangles—and to synaptic resilience. Lithium Chelate 10 mg per capsules per bottle of 60. Recent Research Findings Recent clinical trials have shed light on lithium's potential effectiveness in treating Alzheimer's disease. A significant study published in Alzheimer's & Dementia highlighted that low-dose lithium treatment led to a 25% reduction in the rate of cognitive decline in patients with mild to moderate Alzheimer's compared to a placebo group. Patients receiving lithium showed improved scores on standardized cognitive assessments, underscoring that lithium may not only stabilize mood but also enhance cognitive function. This dual impact makes lithium an exciting option for treatment. The latest headline: lithium may be biologically low  in early memory loss A 2025 Nature  study offers a unifying clue: when scientists examined human brain tissue, lithium was the only trace metal consistently reduced in people with mild cognitive impairment , and it was further bound up and “trapped” by amyloid in Alzheimer’s. In aging mice, restoring small amounts of lithium (in forms that avoid plaque binding) reversed memory decline and molecular aging signatures. This doesn’t prove benefit in humans—but it explains why lithium could be protective and strengthens the case for clinical trials. Safety and Tolerability While lithium shows promise as a treatment for Alzheimer's, safety and tolerability are paramount concerns. Lithium's side effects, particularly renal and thyroid complications, are well-documented. Yet, recent studies suggest that low-dose lithium may be effectively tolerated, especially with appropriate monitoring. Regular blood tests can help maintain lithium levels within a safe therapeutic range, minimizing the risk of adverse effects. For instance, monitoring can prevent complications in approximately 90% of patients when conducted regularly. Future Directions in Research As research interest in lithium expands, several promising areas for future investigation have emerged: Long-term Studies : To fully understand lithium's impact on cognitive decline and brain health, long-term studies tracking patients over several years are necessary. Combination Therapies : Exploring the potential synergy of lithium with other treatments could enhance its overall effectiveness. For example, research indicates that pairing lithium with certain anti-inflammatory medications could improve neuroprotection and cognitive function. Biomarker Development : Developing biomarkers to predict patient responses to lithium treatment would enable personalized therapy plans, ensuring more effective outcomes and reduced risks. Mechanistic Studies : Investigating the molecular mechanisms through which lithium exerts its neuroprotective effects could provide a deeper understanding of its interaction with Alzheimer's pathology. Research laboratory focused on Alzheimer's studies Implications for Patients and Caregivers The potential for lithium as a treatment option presents both hope and challenges for patients and caregivers. Current research offers a glimpse into its ability to slow cognitive decline, an important aspect in an area where effective treatment options are limited. Caregivers and patients should stay updated on emerging research and collaborate with healthcare professionals about potential treatment paths. Engaging with ongoing studies can help navigate the evolving landscape of Alzheimer's treatment and improve management strategies for this complex condition. What do meta-analyses say? Synthesis papers through 2024 suggest a possible reduction in dementia risk  or delayed onset among lithium-exposed individuals, while emphasizing heterogeneity and the urgent need for larger, long-duration randomized trials. Some recent meta-analyses are cautiously positive; others find no clear association  yet—reminding us not to over-interpret small trials. Dosing context: from “micro” to “standard”—and why supervision matters Research has explored three broad territories: Microdose  (e.g., ~300 μg/day): below standard psychiatric dosing; trials report no expected rise  in serum lithium and favorable tolerability, but replication is needed. Low pharmaceutical dose  (e.g., 150–450 mg lithium carbonate/day), aiming for serum ~0.2–0.5 mEq/L  in some protocols; this is where MCI biomarker and cognitive signals have appeared. Standard psychiatric dose  (e.g., 600–1200 mg/day; serum 0.6–1.0 mEq/L ): well established for bipolar disorder, but not routinely used for Alzheimer’s due to side-effect risks and lack of proven superiority in AD. (Illustration 3 is a quick visual guide; it is not  a dosing recommendation.)   NOTE: The Dosages used in this office fall well below the 'Low pharmaceutical dose, ranging from Lithium 10 mg twice a day, to as much as 20 mg twice a day. Moving Forward Lithium's evolving role in treating Alzheimer's disease signifies an exciting narrative in medical research. With unique mechanisms and emerging evidence of efficacy, lithium could become an essential tool in addressing the challenges posed by Alzheimer's. As research progresses, remaining informed about the latest findings is crucial for patients, caregivers, and healthcare providers alike. By fostering collaboration and supporting ongoing studies, we can explore innovative treatments that may one day reshape Alzheimer's care. In the search for effective therapies, lithium shines as a beacon of hope, guiding us closer to better management and comprehension of this complex disease. Safety first: who should not  self-experiment with lithium Lithium can interact with common medications ( ACE inhibitors/ARBs, thiazide and loop diuretics, NSAIDs ) and requires periodic checks of kidney function, thyroid, and serum lithium   when used at pharmaceutical doses. Dehydration and sudden changes in salt intake can raise lithium levels. Even “low-dose” strategies should be individualized and monitored. (These are general principles from geriatric lithium practice; decisions must be clinician-guided.) Where the field is headed The 2025 Nature work sets the stage for mechanism-driven human trials  that test whether carefully formulated, low-dose lithium can prevent  progression from MCI to Alzheimer’s or slow decline in early Alzheimer’s—ideally with biomarker endpoints (tau phosphorylation, amyloid dynamics, neuroinflammation) and rigorous safety monitoring. Several clinical trials are already registered to explore preventive and symptomatic roles. References (selected, accessible) Aron L, et al.   Lithium deficiency and the onset of Alzheimer’s disease.   Nature.  2025. (Mechanistic human tissue + mouse rescue study demonstrating brain lithium depletion in MCI/AD and reversal of aging phenotypes with low-dose lithium in mice.) Nature Forlenza OV, et al.   Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomized controlled trial.   Br J Psychiatry.  2011. (Reduced CSF p-tau; cognitive stabilization with low pharmaceutical dosing.) Cambridge University Press & Assessment Forlenza OV, et al.   Clinical and biological effects of long-term lithium treatment in older adults with amnestic MCI: randomized clinical trial.   Br J Psychiatry.  2019. (Longer-term cognitive stability and CSF Aβ1-42 increase.) PubMed Nunes MA, et al.   Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer’s disease.   Curr Alzheimer Res.  2013. (15-month double-blind RCT; 300 μg/day stabilized MMSE vs. placebo.) PubMed Lu Q, et al.   Lithium therapy’s potential to lower dementia risk and postpone onset: meta-analysis.   Dement Geriatr Cogn Disord.  2024. (Suggests risk reduction with exposure; underscores need for trials.) PubMed Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician